Clinical Trials Browser

Phase 2 × Withdrawn × regorafenib × Clear all

NCT05900648 2024-04-29

Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05582031 2023-06-07

REFIT-MSS

Phase 2 Withdrawn

GastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Anus Neoplasms, Sarcoma, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT02287727 2016-10-12

Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment

Phase 2 Withdrawn

Gastrointestinal

Rectal Neoplasms